Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer

Helper Type ◽

Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer

Breast Cancer Research ◽

10.1186/s13058-015-0584-1 ◽

2015 ◽

Vol 17 (1) ◽

Cited By ~ 36

Author(s):

Jashodeep Datta ◽

Erik Berk ◽

Shuwen Xu ◽

Elizabeth Fitzpatrick ◽

Cinthia Rosemblit ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Therapy ◽

Pathologic Response ◽

T Helper ◽

Her2 Positive ◽

Immune Correlate ◽

Helper Type ◽

Anti-HER2 CD4+ T-Helper Type 1 Immune Response is Superior to Breast MRI for Assessing Response to Neoadjuvant Therapy in Patients with HER2-Positive Breast Cancer

Annals of Surgical Oncology ◽

10.1245/s10434-016-5651-z ◽

2016 ◽

Vol 24 (4) ◽

pp. 1057-1063 ◽

Cited By ~ 3

Author(s):

Lucy M. De La Cruz ◽

Elizabeth S. McDonald ◽

R. Mick ◽

Jashodeep Datta ◽

Nadia F. Nocera ◽

...

Keyword(s):

Breast Cancer ◽

Immune Response ◽

Neoadjuvant Therapy ◽

Breast Mri ◽

T Helper ◽

Her2 Positive ◽

Helper Type ◽

Review of treatment strategies for HER2 positive breast cancer and their implementation in a major Swiss hospital

10.1055/s-0040-1710671 ◽

2020 ◽

Author(s):

F Geissler ◽

M Vetter ◽

A Schoetzau ◽

C Montavon ◽

C Kurzeder ◽

...

Keyword(s):

Breast Cancer ◽

Treatment Strategies ◽

Her2 Positive ◽

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy: Sequential analysis

10.26226/morressier.596dfd55d462b80292386fa4 ◽

2017 ◽

Author(s):

You-Jeong Seo

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Sequential Analysis ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Pik3ca Mutations ◽

Hypoxia up-regulates ID proteins in Luminal and HER2-positive breast cancer cell lines

10.26226/morressier.5b4709836f4cb30010951ad8 ◽

2018 ◽

Author(s):

Gloria Peiro Cabrera

Keyword(s):

Breast Cancer ◽

Cell Lines ◽

Cancer Cell ◽

Breast Cancer Cell ◽

Breast Cancer Cell Lines ◽

Her2 Positive ◽

Id Proteins ◽

Positive Breast Cancer Cell ◽

FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer

10.31525/cmr-24bd324 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies

10.31525/cmr-24bb59f ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Treatment Option ◽

Her2 Positive ◽

New Treatment ◽

FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies

10.31525/cmr-24bb467 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Treatment Option ◽

Her2 Positive ◽

New Treatment ◽

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer

10.31525/ct1-nct03847818 ◽

2000 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Local Advanced or Metastatic, HER2 Positive Breast Cancer.

10.31525/ct1-nct03944499 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Solid Tumors ◽

Phase 1 ◽

Advanced Solid Tumors ◽

Her2 Positive ◽

Phase 1 Study ◽

Local Advanced ◽